OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Rheumatology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Editorial introduction	251
Giant cell arteritis: update on pathogenesis and clinical implications	67
Current approach to muscle imaging in myositis	63
Epidemiology and outcomes of rheumatoid arthritis	55
Current views on lupus in children	52
Update on antineutrophil cytoplasmic autoantibody vasculitis in children	51
Urticarial vasculitis	51
Polymyalgia rheumatica and giant cell arteritis: diagnosis and management	48
Selective immunoglobulin E deficiency: an overlooked hypogammaglobulinemia and its association with rheumatoid arthritis	39
Editorial introductions	36
What's next in psoriatic arthritis therapy? A look at the pipeline	36
Osteoporosis epidemiology using international cohorts	35
Juvenile Behçet syndrome: a contemporary view and differential diagnosis in pediatric practice	35
Axial spondyloarthritis guidelines – aiming for maximum impact	30
Patient-reported outcomes in systemic sclerosis: insights into quality of life and disease burden	27
Composite measures to assess disease damage, disease severity and treatment response in systemic sclerosis clinical trials	25
Rheumatoid arthritis – the challenge of heterogeneity	24
Comorbidities in idiopathic inflammatory myopathies: population-based evidence on risk subgroups and implications for delivery of care	22
A comprehensive review of systemic sclerosis–primary biliary cholangitis overlap: emerging evidence for a distinct clinical subtype	22
Recent advances in the use of machine learning and artificial intelligence to improve diagnosis, predict flares, and enrich clinical trials in lupus	21
Editorial introductions	20
Updates on translational and clinical research in systemic sclerosis	20
The gut microbiota in spondyloarthritis: an update	20
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis	19
Editorial introductions	19

Editorial introduction	18
Editorial introductions	18
VEXAS syndrome: an adult-onset autoinflammatory disorder with underlying somatic mutation	18
Pathogenesis of skin damage in lupus: recent advances and future directions	17
Insights into the pathogenic role of neutrophils in systemic lupus erythematosus	16
Management of cutaneous manifestations of systemic sclerosis: current approaches and emerging therapies	16
Understanding the gastrointestinal microbiome in systemic sclerosis: methodological advancements and emerging research	16
Rheumatoid arthritis contributes to comorbidity burden through systemic inflammation and autoimmunity: examples of atherosclerotic cardiovascular disease, interstitial lung disease, and depression	15
The role of neutrophil extracellular traps in inflammatory rheumatic diseases	15
Defining and managing flares in axial spondyloarthritis	15
Pathogenesis of vasculopathy in systemic sclerosis and its contribution to fibrosis	14
Chimeric antigen receptor T-cell therapy in rheumatology: B-cell depletion 2.0	14
Epidemiology of myositis	14
Health inequities in the rheumatic diseases of childhood	14
How common is vasculitis: what do population-based data tell us?	14
Emerging synovial cell states in rheumatoid arthritis as potential therapeutic targets	14
Nonsteroidal anti-inflammatory drugs and cardiovascular disease risk in spondyloarthritis-spectrum diseases	14
Is it time to move on from pelvic radiography as the first-line imaging modality for suspected sacroiliitis?	13
New developments related to lung complications in pediatric rheumatic disease	13
Editorial introductions	13
Advances in the diagnosis and treatment of Sjögren disease	12
Diagnosis and management of primary heart involvement in systemic sclerosis	12
Environmental and occupational contributors to autoimmune, inflammatory, and musculoskeletal rheumatic disease: a review of emerging evidence and clinical implications	12
Editorial introduction	12
AI am the future: artificial intelligence in pediatric rheumatology	12
Investigating gout flares: beyond a definition	12
Biomarker discovery in psoriatic disease	12
Management of postinfectious inflammatory arthritis	11
Exploring challenges in the management and treatment of inclusion body myositis	11
Eosinophilic granulomatosis with polyangiitis: recent therapeutic advances	11
Epidemiology of osteoarthritis: literature update 2022–2023	11
Heart involvement in systemic sclerosis: emerging concepts	11
Vasculitis and the NLRP3 inflammasome	11
Advances in the diagnosis of multiorgan involvement in systemic sclerosis: a focus on MRI	10
Decoding vascular dysfunction in systemic sclerosis: from endothelial damage to clinical implications	10
Current management of giant cell arteritis and its complications	10
Animal models in systemic sclerosis: an update	10
Update on streptococcal-associated rheumatic disease	10
Emerging biologic therapies for systemic lupus erythematosus	10
Gastrointestinal involvement in systemic sclerosis: pathogenesis, assessment and treatment	10
Gastrointestinal disease in systemic sclerosis: the neglected organ system?	10
The contribution of endothelial cells to tissue fibrosis	10
New therapies in anti-MDA5 antibody-positive dermatomyositis	9
Pregnancies in women with antineutrophil cytoplasmatic antibody associated vasculitis	9
Biologic disease-modifying antirheumatic drugs to treat multisystem inflammatory syndrome in children	9
Recent developments in the synovial fibroblast pathobiology field in rheumatoid arthritis	9
What have we learned about systemic sclerosis from the EUSTAR database?	9
Biomarkers in juvenile idiopathic arthritis: towards precision diagnosis and personalized therapy?	9
Editorial introduction	9
Revisiting the CD40-CD40L axis: from mechanistic insight to therapeutic renewal in autoimmune disease	9

Treatment of systemic vasculitis	9
Treatment of interstitial lung disease in systemic sclerosis: guidelines and new clinical trial results	8
Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children	8
Emerging cellular and immunotherapies for systemic sclerosis: from mesenchymal stromal cells to CAR-T cells and vaccine-based approaches	8
Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis	8
Calcinosis in systemic sclerosis	7
What are mice teaching us about psoriatic arthritis?	7
Update on muscle imaging in myositis	7
Clinical endpoints in myositis: challenges and ways forward	7
Describing calcium pyrophosphate deposition: undoing the tower of Babel!	7
Treatment of juvenile localized scleroderma: current recommendations, response factors, and potential alternative treatments	7
Osteoarthritis gene therapy in 2022	7
Cholinergic anti-inflammatory pathway and vagus nerve stimulation in rheumatoid arthritis	6
Neurovascular dysregulation in systemic sclerosis: novel insights into pathophysiology, diagnosis, and treatment utilizing invasive cardiopulmonary exercise testing	6
Epidemiology of systemic vasculitis	6
Recent advances in immunometabolism in rheumatic diseases	6
A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018–2024	6
Autologous hematopoietic stem cell transplant for systemic sclerosis associated interstitial lung disease	6
Not all benign: disease course, complications, and sequalae of chronic recurrent multifocal osteomyelitis in children	6
Quo vadis reactive arthritis?	6
Contribution of keratinocytes to dermal fibrosis	6
Complications of severe acute respiratory syndrome coronavirus 2 infection in children	6
Editorial introductions	6
Go or no-go for treat-to-target in axial spondyloarthritis?	6
Autoantibodies in rheumatoid arthritis – rheumatoid factor, anticitrullinated protein antibodies and beyond	6
Editorial introduction	5
Should CAR-T cells be used as monotherapy?	5
The complement system in antineutrophil cytoplasmic antibody-associated vasculitis: pathogenic player and therapeutic target	5
Management of patients with antiphospholipid antibodies or antiphospholipid syndrome during pregnancy	5
Recent advances on neutrophil dysregulation in the pathogenesis of rheumatic diseases	5
Acute and postacute COVID-19 outcomes for patients with rheumatoid arthritis: lessons learned and emerging directions 3 years into the pandemic	5
Disease modification in axial spondyloarthritis – still a controversy?	5
Rethinking spondyloarthritis: beyond lumping and splitting	5
Spatial transcriptomics: challenges and future directions in musculoskeletal diseases	5
Neuropsychiatric systemic lupus erythematosus – current and novel treatments	5
Calcinosis in systemic sclerosis	5
Editorial introduction	5
Genetic and epigenetic factors shape phenotypes and outcomes in systemic lupus erythematosus – focus on juvenile-onset systemic lupus erythematosus	5
Renal disease in pediatric rheumatology	5
Omics studies in Behçet's disease	5
Scleroderma autoantibodies in guiding monitoring and treatment decisions	5
Updates in juvenile dermatomyositis: pathogenesis and therapy	5
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives	4
Editorial myositis and myopathies	4
Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities	4
Decoding VEXAS syndrome: emerging insights into pathogenesis and clinical management	4
The impact of omics research on our understanding of osteoarthritis and future treatments	4
Advances in osteoarthritis imaging	4
Vaccination updates and special considerations for systemic lupus erythematosus patients	4
Challenges of caring for transgender and gender diverse patients with rheumatic disease: presentation of seven patients and review of the literature	4
Regulatory T cells and systemic vasculitis	4
Human leucocyte antigen-B27 testing in clinical practice: a global perspective	4
Drug therapy in juvenile spondyloarthritis	4
Methods for objective assessment of skin involvement in systemic sclerosis	4
Update on autoantibodies and related biomarkers in autoimmune inflammatory myopathies	4
Updates in uricase therapy for gout	4
Harnessing artificial intelligence to advance insights in systemic sclerosis skin and lung disease	4
Isolated aortitis – is it truly isolated? An approach to diagnosis and management	3
SGLT-2 inhibitors: new horizons for rheumatologists	3
Human genetics of Whipple's disease	3
An update on inflammation in antiphospholipid syndrome	3
Microbiome dynamics in rheumatic diseases	3
Current efforts and historical perspectives on classification of idiopathic inflammatory myopathies	3
Gastrointestinal manifestations of systemic sclerosis: current approaches and emerging therapies	3
An update on topical therapies for psoriasis	3
Novel therapies in juvenile idiopathic arthritis	3
Rheumatologic immune checkpoint inhibitor-related adverse events	3
Janus kinase inhibitors: efficacy and safety	3
Update on treatment responses and outcome measure development in chronic nonbacterial osteomyelitis	3
Understanding psoriatic disease at single-cell resolution: an update	3
Vasculitis associated with nonhematological malignancies	3
New molecular targets in the treatment of rheumatoid arthritis	3
Pathophysiologic implications and therapeutic potentials of telocytes in multiorgan fibrosis	3